Two people dead after receiving potentially contaminated Moderna COVID-19 vaccines in Japan; Biogen offers its controversial and expensive Alzheimer disease treatment for free to boost prescriptions; COVID-19 infection with the Delta variant may more than double the risk of hospitalization.
Following the suspension of Moderna’s COVID-19 vaccine in Japan on Thursday due to concerns over a contamination risk, 2 people have died after receiving doses from a batch suspected as contaminated, according to CNN. With 1.63 million doses suspended in Japan as of August 26, Takeda Pharmaceutical Company, which distributes the Moderna vaccine in the country, said that a causal link between the vaccine and the deaths has not yet been established. However, the potential contaminant has been described as “particulate matter,” with results from laboratory tests to be made available in the next few days.
Amid slow claim reviews by Medicare, Biogen is offering aducanumab (Aduhelm), its controversial and expensive Alzheimer disease drug, free of charge to some patients. As reported by Reuters, the $56,000-a-year price tag and uncertain reimbursement from Medicare has led to division among physicians considering its use, along with the drug’s lack of clinical benefit observed in studies. To expedite treatment adherence, Biogen’s access program will provide aducanumab for free, with Florida’s First Choice Neurology having already received doses of the monthly infusion treatment.
According to study findings published this past Friday in The Lancet Infectious Diseases, COVID-19 infection with the Delta variant may more than double the risk of hospitalization compared with the Alpha variant. As reported by Forbes, health care data from 43,338 positive coronavirus cases in England between March 29 and May 23 indicated that the risk of hospitalization increased 2.26-fold in patients infected with the Delta variant, after adjusting for confounding factors. Notably, only 1.8% of assessed cases included individuals who had received both vaccine doses, with the majority of participants being partially vaccinated or unvaccinated.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen